Calcitriol - Galderma
Alternative Names: Silkis; VecticalLatest Information Update: 25 Sep 2021
At a glance
- Originator Savient Pharmaceuticals
- Developer Galderma
- Class Antipsoriatics; Chemoprotectants; Dihydroxycholecalciferols; Osteoporosis therapies; Small molecules; Vitamin D analogues
- Mechanism of Action Calcitriol receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Plaque psoriasis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Plaque-psoriasis(In adolescents, In children) in USA (Topical, Ointment)
- 01 Jul 2014 Galderma initiates enrolment in a phase IV trial for Plaque psoriasis (In children) in USA (NCT02186665)
- 28 Mar 2014 Clinical trials in Plaque psoriasis (In children, In adolescents) in USA (Topical)